Abstract PS3-10-28: Randomized phase II trial evaluating three anti-diarrheal prophylaxis strategies in patients (pts) with HER2+/HR+ early breast cancer (EBC) treated with extended adjuvant neratinib (dianer geicam/2018-06)
Year: 2026
Type: conference-abstract
Source: Clinical Cancer Research
Authors: J. Gil-Gil, M. Ruíz-Borrego, E. Carrasco, Y. Izarzugaza, C. Martínez-Vila, E. Galve, B. López-Barajas, E. Adrover, T. Silovski, M. Valero-Arbizu, Á. Guerrero-Zotano, S. González-Santiago, M. Echarri, A. Cano-Jiménez, A. Vethencourt-Casado, M. De Laurentis, C. Bueno-Muiño, B. Adamo, R. Andrés, C. Villanueva, F. Rojo, M. Casas, P. Wilson, J. Suissa, V. Adams, M. Martin
Institutions: Institut Català d'Oncologia, GEICAM – Spanish Breast Cancer Group, Hospital Universitario Virgen del Rocío, Hospital Universitario Fundación Jiménez Díaz, Althaia, Hospital de Basurto, Complejo Hospitalario Universitario de Albacete, University Hospital Centre Zagreb, University of Zagreb, Hospital Quirónsalud Sagrado Corazón, Fundación Instituto Valenciano de Oncología, Hospital San Pedro de Alcántara, Hospital Universitario Severo Ochoa, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Hospital Universitario Infanta Cristina, Hospital Clínic de Barcelona, Hospital Clínico Universitario Lozano Blesa, Clinique Clémentville, Puma Biotechnology (United States), Pierre Fabre (France), Breast International Group, Universidad Complutense de Madrid, Instituto de Investigación Sanitaria Gregorio Marañón
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7129230438
Cites:
Cited by:
Related to: